Personalized use of newer diabetes medicines for Type 2 diabetes
Official title: Building Personalized Therapeutic Strategies for Newer Glucose-Lowering Drugs in People with Type 2 Diabetes
Funded at Purdue University · NIH-11571362 · Data updated 2026-11-12
Aiming to tailor use of newer glucose-lowering drugs for people with type 2 diabetes to improve health and access in real-world settings.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Purdue University NIH-funded |
| Lab location | 1 site (West Lafayette, United States) |
| Project start | July 20, 2022 |
| Project end | June 30, 2027 |
| Funding year | 2025 |
| Award (this year) | $231,610 |
| NIH project number | 7R01DK133465-05 |
| Project ID | NIH-11571362 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with type 2 diabetes who are candidates for newer glucose-lowering drugs and who have varying levels of access and resources.
✕Less likely to help
Patients who do not require newer GLDs or for whom these drugs are not appropriate due to medical reasons.
What this research studies
This project looks at how to customize when and how to use newer, higher-cost diabetes medicines so that people with type 2 diabetes can get the best outcomes without financial hardship. It will examine data from real-world patient experiences to understand which patients benefit most from these drugs and how to optimize treatment over time. The goal is to generate practical guidance that clinicians can use to choose therapies that improve heart and kidney health while considering costs. The study builds on prior work showing benefits of newer GLDs and seeks to fill gaps about who benefits most in diverse, real-life populations.
Why it matters
Potential benefit: If successful, it could help clinicians choose better, more affordable treatment plans for people with type 2 diabetes.
How similar studies have gone: Prior CER work suggests some personalized strategies work, but knowledge gaps remain about who benefits most from newer GLDs in real practice.
Where this research is happening
-
Purdue University
West Lafayette, United States Active
Researchers
- Principal investigator: Guo, Jingchuan — Purdue University
- Study coordinator: Guo, Jingchuan
Related research
Other NIH-funded projects on the same topics.
-
Subtyping Core for Research on the Causes of Type 2 Diabetes (SCORE-T2D)
A new U01 grant from a university research team aims to understand why Type 2 diabetes differs so much between people and how to tailor prevention and treatment.
-
Michigan Diabetes Project: A Peer-Led Self-Management Program for Adults with Type 2 Diabetes
A peer-led self-management program for adults with type 2 diabetes is being tested to see if it improves blood sugar control and daily diabetes care.
-
Alzheimer’s and dementia risk in people with prediabetes or type 2 diabetes
This grant aims to understand why some older adults with prediabetes or type 2 diabetes develop memory problems or dementia.
-
Alzheimer’s and related dementia in older adults with prediabetes or type 2 diabetes
This grant aims to understand why cognitive problems occur in people 65 and older who have prediabetes or type 2 diabetes, using data from a long-running diabetes study to identify what drives memory and thinking decline.
-
Understanding why youth develop type 2 diabetes and how to prevent it
A nationwide study aims to unravel why some teens with obesity develop type 2 diabetes while others don’t, and to identify factors that could help prevent it.
-
Understanding why youth develop type 2 diabetes and how to prevent it
A study at Baylor College of Medicine is exploring why some youths with obesity develop type 2 diabetes during puberty and how to stop it from getting worse.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.